Thank you to our speakers, sponsors, and delegates who joined us in XXX for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Accelerating More Sensitive, Quantitative & Predictive Serological & Imaging Biomarkers to Transform Clinical Development in the CNS
With the Donanemab ADCOM hailing fluid biomarkers as a deciding factor in the unanimous decision, improved plasma ptau 217 markers and PET tracers, and α-syn self-seeding assay sensitivity and enhancing NFL utility beyond SOD-1 ALS, 2024 has opened the floodgates for biomarker innovation.
The 2nd Fluid & Imaging Biomarkers & Endpoints in Neuroscience forum united biomarker discovery scientists, imaging experts, neuroscience clinical program leads, and regulatory leaders to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.
October 2024, joined 50+ biomarker discovery scientists, imaging experts, neuroscience clinical program leaders, and regulatory leaders from renowned organizations like Alector, Biogen, Bristol Myers Squibb, Eli Lilly, Eisai, Pfizer, Takeda, Regeneron, and the Michael J. Fox Foundation and many more at the ultimate unique industry-focused networking opportunity to advance precision medicine in neurodegenerative and neuroinflammatory diseases.
2024 World-Class Speaker Faculty Included:
Katia Catherine Karalis, MD PhD
Executive Director, RGC, Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Pallavi Sachdev
Executive Director Translational Science, Clinical Evidence Generation, Deep Human Biology (CEG DHBL)
Eisai